Real-World Efficacy and Safety of Sintilimab-Based Regimens against Advanced Esophageal Cancer: A Single-Center Retrospective Observational Study

Table 4

Adverse events related to treatment based on CTCAE 5.0.

Adverse events	Grades 1-2	Grade 3	Grade 4
Anemia	35 (70.0)	2 (4.0)	0
Decrease in white blood cell count	31 (62.0)	1 (2.0)	0
Nausea/vomiting	26 (52.0)	2 (4.0)	0
Hypoproteinemia	21 (42.0)	0	0
Decrease in neutrophil count	18 (36.0)	7 (14.0)	0
Pneumonia	17 (34.0)	4 (8.0)	1 (2.0)
Decrease in platelet count	14 (28.0)	1 (2.0)	1 (2.0)
Increase in bilirubin	9 (18.0)	0	0
Increase in alanine aminotransferase	4 (8.0)	3 (6.0)	0
Rash	4 (8.0)	1 (2.0)	0
Increase in creatinine	3 (6.0)	1 (2.0)	0
Increase in aspartate aminotransferase	3 (6.0)	2 (4.0)	0

Data are number (%).